Dizal Jiangsu Pharmaceutical Co Ltd Relative Valuation - Dizal Jiangsu Pharmaceutical Co Ltd - Alpha Spread
D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 35.99 CNY -1.83% Market Closed
Market Cap: 14.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Relative Value

The Relative Value of one Dizal Jiangsu Pharmaceutical Co Ltd stock under the Base Case scenario is 27.06 CNY. Compared to the current market price of 35.99 CNY, Dizal Jiangsu Pharmaceutical Co Ltd is Overvalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
27.06 CNY
Overvaluation 25%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
57
vs Industry
16
Median 3Y
93.3
Median 5Y
93.3
Industry
7.7
Forward
37.3
vs History
vs Industry
Median 3Y
-16.6
Median 5Y
-16.6
Industry
23.9
Forward
-13.9
vs History
vs Industry
Median 3Y
-20.3
Median 5Y
-20.3
Industry
22.2
vs History
vs Industry
Median 3Y
-25.5
Median 5Y
-25.5
Industry
24
vs History
19
vs Industry
4
Median 3Y
11
Median 5Y
11
Industry
2.5
vs History
57
vs Industry
12
Median 3Y
91.2
Median 5Y
91.2
Industry
7.4
Forward
36.4
vs History
57
vs Industry
9
Median 3Y
94.6
Median 5Y
94.6
Industry
8.5
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-15.4
Industry
5.1
Forward
-13.1
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-15.4
Industry
4.7
Forward
-12.3
vs History
vs Industry
Median 3Y
-19.7
Median 5Y
-19.7
Industry
6.6
vs History
vs Industry
Median 3Y
-18.1
Median 5Y
-18.1
Industry
4.7
vs History
65
vs Industry
11
Median 3Y
24.6
Median 5Y
24.6
Industry
4.7

Multiples Across Competitors

Competitors Multiples
Dizal Jiangsu Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
14.7B CNY 85.1 -13.4 -13 -13
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 28
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
CN
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Average P/E: 57.6
Negative Multiple: -13.4
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Average EV/EBITDA: 47.8
Negative Multiple: -13
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A

See Also

Discover More
Back to Top